Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Hosted on MSN20d
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...
AOL29d
This Company Just Initiated a Quarterly Dividend: Time to Buy?
There is nothing wrong with paying dividends and buying back shares, but in Regeneron's case, management is, apparently, prioritizing the latter. As the company's CEO, Leonard Schleifer ...
Hosted on MSN27d
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
CEO Leonard Schleifer highlighted 10% revenue growth ... expressed increased concerns about competitive pressures on EYLEA. Regeneron capped 2024 with strong revenue growth and significant ...
pharmaphorum1mon
US snaps up first supplies of Regeneron’s COVID-19 antibody
Hard on the heels of Regeneron moving its COVID-19 antibody ... use authorization is granted,” said Regeneron’s CEO Leonard Schleifer. “This manufacturing and supply agreement with BARDA ...